Scafetta R, Troiano R, Gullotta C, Guarino A, et al. Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+?/HER2?- breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study. Eur J Cancer 2026;239:116703.
PMID: 41921366